Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Repeated Exposure to Adjuvanted vs Non-adjuvanted QIV in Children
NCT02583256Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in influenza (4 arms), sponsored by CSL Seqirus. Primary endpoints: Geometric Mean Titer (HI) Against Homologous Strains at Day 22 and Geometric Mean Titer Ratio (HI) Against Homologous Strains at Day 22. Started Jan 2016; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02583256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583256.